Abstract
The serotonin 5-HT2C receptor is a G-protein-coupled receptor and is one of the 14 subtypes that constitutes the serotonin receptor family. Agonists of 5-HT2C have been implicated as potential treatments for diseases of significant unmet medical need, including obesity and schizophrenia. Despite approximately 10 years of discovery efforts, 5-HT2C agonists have only recently advanced into the clinic, likely because many of the early drug discovery efforts experienced significant difficulties with attaining receptor selectivity. Several of these issues related to receptor selectivity have now been overcome, resulting in the entry of compounds into advanced clinical trials. This review summarizes the progress in 5-HT2C agonist discovery and clinical development over the last 3 years. [sw1]what are the several issues - several issues relating to receptor selectivity?
MeSH terms
-
Animals
-
Anti-Obesity Agents / chemistry
-
Anti-Obesity Agents / pharmacology*
-
Anti-Obesity Agents / therapeutic use
-
Antipsychotic Agents / chemistry
-
Antipsychotic Agents / pharmacology*
-
Antipsychotic Agents / therapeutic use
-
Benzazepines / pharmacology
-
Drug Design*
-
Drug Evaluation, Preclinical
-
Humans
-
Molecular Structure
-
Mood Disorders / drug therapy
-
Mood Disorders / metabolism
-
Obesity / drug therapy
-
Obesity / metabolism
-
Ocular Hypertension / drug therapy
-
Ocular Hypertension / metabolism
-
Receptor, Serotonin, 5-HT2C / metabolism
-
Serotonin 5-HT2 Receptor Agonists*
-
Serotonin Receptor Agonists / chemistry
-
Serotonin Receptor Agonists / pharmacology*
-
Serotonin Receptor Agonists / therapeutic use
-
Treatment Outcome
Substances
-
Anti-Obesity Agents
-
Antipsychotic Agents
-
Benzazepines
-
Receptor, Serotonin, 5-HT2C
-
Serotonin 5-HT2 Receptor Agonists
-
Serotonin Receptor Agonists
-
lorcaserin